je.st
news
Tag: melanoma
Viagra - Melanoma Lawsuits Mounting
2016-02-18 17:07:11| Biotech - Topix.net
The Judicial Panel on Multidistrict Litigation will hold a hearing to consider a request to establish coordinated national litigation against the manufacturers of Viagra. The Judicial Panel is a group of federal judges who meet every other month to consider requests for the establishment of multidistrict litigation for cases involving multiple plaintiffs, which usually include drug and medical device product liability claims, class actions, securities lawsuits, and claims involving mass accidents or natural disasters.
Tags: viagra
mounting
lawsuits
melanoma
FDA Approves Expanded Indication for Mercks KEYTRUDA (pembrolizumab) for the Treatment of Patients with Advanced Melanoma
2015-12-18 22:05:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. KEYTRUDA is Now the First and Only Anti-PD-1 Therapy to Achieve Superior Overall Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded indication for KEYTRUDA (pembrolizumab), the companys anti-PD-1 (programmed death receptor-1) therapy, to include the first-line treatment of patients with unresectable or metastatic melanoma. Language: English Contact: MerckMedia Contacts:Pamela Eisele, 267-305-3558orAn Phan, 908-255-6325orInvestor Contacts:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: with
advanced
treatment
expanded
Merck Announces Initial Results for KEYTRUDA (pembrolizumab) with Novel Immunotherapy Combinations from Three Investigational Studies Presented at the Society for Melanoma Research International Congress
2015-11-21 22:30:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. In Addition, Longer Term Follow-Up Single-Agent Data for KEYTRUDA Shows Continued Superior Overall Response Rate and Progression Free Survival Compared to Ipilimumab KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced findings from three studies investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in combination with three other immunotherapies epacadostat, IMLYGICTM (talimogene laherparepvec), and ipilimumab in patients with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, (267) 305-3558orAn Phan, (908) 255-6325orInvestors:Teri Loxam, (908) 740-1986orJustin Holko, (908) 740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: results
international
research
society
Incyte and Merck Expand Clinical Collaboration to Include Phase 3 Study Investigating the Combination of Epacadostat with Keytruda (pembrolizumab) as First-line Treatment for Advanced Melanoma
2015-10-13 13:30:03| Merck.com - Product News
Dateline City: WILMINGTON, Del. and KENILWORTH, N.J. Pivotal study to evaluate Incytes IDO1 inhibitor in combination with Mercks anti-PD-1 therapy in patients with advanced or metastatic melanoma WILMINGTON, Del. and KENILWORTH, N.J. -- Incyte Corporation (Nasdaq: INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the expansion of the companies ongoing clinical collaboration to include a Phase 3 study evaluating the combination of epacadostat, Incytes investigational selective IDO1 inhibitor, with Keytruda (pembrolizumab), Mercks anti-PD-1 therapy, as first-line treatment for patients with advanced or metastatic melanoma. Language: English read more
Tags: for
advanced
include
study
KEYTRUDA (pembrolizumab) Receives New Draft Recommendation from National Institute for Health and Care Excellence (NICE) in U.K. for First-Line Treatment for Advanced Melanoma
2015-10-09 13:00:00| Merck.com - Corporate News
Dateline City: KENILWORTH, N.J. KEYTRUDA is Currently Approved in 39 Countries, including the United States and throughout the European Union KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the National Institute for Health and Care Excellence (NICE) of the United Kingdom (U.K.) has issued a draft recommendation, in the form of a Final Appraisal Determination (FAD), recommending KEYTRUDA (pembrolizumab) as a first-line treatment option for adults with advanced melanoma. Language: English Contact: MerckMedia:Pamela Eisele, 267-305-3558orAn Phan, 908-236-1130orInvestors:Teri Loxam, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: for
advanced
health
care
Sites : [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] next »